Registry of Outcomes of Dezawa MuseCells® (NCT07645989) | Clinical Trial Compass
RecruitingNot Applicable
Registry of Outcomes of Dezawa MuseCells®
United States, Mexico5,000 participantsStarted 2026-07-01
Plain-language summary
The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.
The Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.
Who can participate
Age range
89 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Received Dezawa MuseCells® as Part of Routine Clinical Care
. Patients ( and/or authorized representative) capable of providing informed consent and participating in long-term follow-up.
. Willingness to Complete Online Survey Assessments
. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.
. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.
. Ability to Communicate in the Registry's Supported Language
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is listed as a registry rather than a standard clinical trial phase — what does that mean for what we'd actually learn about whether Muse cells are safe and effective for my specific condition like osteoarthritis or wound care?
2Since the trial is measuring change in patient-reported symptom severity, who decides what counts as a meaningful improvement, and how would my symptoms be tracked over time if I were to participate?
3Muse cells are a relatively new type of cell therapy — what does my doctor know about the current evidence base for Dezawa MuseCells, and are there more established treatments I should consider first before thinking about a registry like this?
4This registry covers a wide range of conditions including osteoarthritis, pain, wound care, and longevity — how would my doctor determine whether my particular diagnosis is a reasonable fit for the kind of data this registry is collecting?
5Since this is a registry study that tracks real-world outcomes rather than a controlled trial, does participating mean I would receive Muse cell treatment as part of the registry, and if so, what is already known about the risks of that treatment?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Patient Reported Symptom Severity
Timeframe: Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.
. Participants must be able to read and respond to registry surveys in the designated study language.
. Enrollment Within 12 Months of MuseCell® Administration
Exclusion criteria
. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit/non-licensed product cannot be included.
. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.
. Inability to Participate in Long-Term Digital Follow-Up
. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes
. History of Malignancy Diagnosed Within the Past 12 Months
. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.
. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality
. Use of Non-Licensed or Counterfeit "Muse-like" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.